Latest From MacroGenics Inc.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
The company expects to file an NDA for tucatinib in the first quarter after a pivotal trial showed a significant improvement in PFS and OS for patients with advanced or metastatic HER2-positive breast cancer, including those with brain metastases.
The latest drug development news and highlights from our US FDA Performance Tracker.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- MacroGenics Inc.
- Senior Management
Scott Koenig, MD, PhD, Pres. & CEO
James Karrels, SVP, CFO
Ezio Bonvini, MD, SVP, Research & CSO
Eric Risser, VP, Bus. Dev. & Portfolio Mgmt. & CBO
Jon Wigginton, MD, SVP, Clin. Dev. & CMO
- Contact Info
Phone: (301) 251-5172
9704 Medical Center Dr.
Rockville, MD 20850
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.